Intellia Therapeutics is approaching a key FDA decision in March 2027 for lonvo-z, potentially the first in vivo CRISPR therapy targeting hereditary angioedema. Phase 3 trials showed about 87% reduction in attacks and a strong safety profile, suggesting lonvo-z could be a transformative one-time treatment in a market currently dominated by costly options. Commercial success will depend on acceptance by payers, doctors, and pricing strategies, with initial revenues expected to be modest but with significant long-term potential if approved. Additionally, Intellia's Nex-z program for ATTR amyloidosis has resumed Phase 3 trials after a clinical hold, though safety and study design remain critical challenges.
Intellia's upcoming FDA decision in March 2027 provides context for health sector trading. As of Nov 07, 2026 03:21 WIB, 83 of 150 priced health-sector US stocks on Pluang rose while 67 fell. Notable movers include GMED at USD 71.10 with a -12.78% change, SMMT at USD 15.95 with +12.37%, and DNA at USD 11.08 with +11.24%.
Arcutis Biotherapeutics awarded 58,500 restricted stock units and options for 17,000 shares to six new employees as an inducement to join the company. The grants, approved under Nasdaq Listing Rule 5635(c)(4), vest over four years with specific sched...
The music duo for KING + COUNTRY released the Drummer Boy (Original Motion Picture Soundtrack) to coincide with the nationwide launch of their Christmas film DRUMMER BOY. The soundtrack features original songs by Joel and Luke Smallbone, reimagined C...
HMG Strategy is holding its first Tennessee C-Level Technology Leadership Summit on November 13 at W Nashville, bringing together CIOs, CISOs, CTOs, and senior tech executives from across Tennessee and the Mid-South. The summit will focus on AI, cybe...
Two large transfers of Tether USDt (USDT) totaling over 81 million tokens were recorded moving from unidentified wallets to Coinbase in early November. On November 1, 40 million USDT moved to Coinbase, followed by a 41,048,700 USDT transfer on Novemb...
OpenAI has raised $11 billion so far in a new funding round valuing the company at $1.25 trillion, with the round expected to close at around $20 billion. This funding round is smaller than the initially targeted $30 billion. The AI market faces unce...
